Synthesis and structure–activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists
J. Robert Merritt, Jianping Chao, Lynne Ozgur, Laura L. Rokosz, Tara M. Stauffer, Kingsley H. Nelson(United States Pharmacopeial Convention), Wei Wang(Capital Medical University), Ge Li(Anhui Medical University), Bernd Kaiser, John J. Baldwin(United States Pharmacopeial Convention), Adriane Schilling(United States Pharmacopeial Convention), Michael P. Dwyer, Arthur G. Taveras
Cited by 47
Related Papers
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
|Drug Resistance Updates|2022|257
Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib
|Journal for ImmunoTherapy of Cancer|2020|153
Targeting Piezo1 unleashes innate immunity against cancer and infectious disease
|Science Immunology|2020|151
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
|Pharmacological Reviews|2024|127